2Gordon AN, Tonda M, Sun S, et al. Long - term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer [J]. Gynecol Oncol, 2004, 95 (1) : 1.
3Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer [J]. Obstet Gynecol, 2002, 99 : 1008.
4Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?[J].Cancer, 2004, 100:1152.
5Gronlund B, Lundvall L, Christensen I J, et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum [J]. Eur J Surg Oncol, 2005, 31 (1) : 67.
6Pfisterer J, Harter P, Canzler U, et al. The role of surgery in recurrent ovarian cancer[J].Int J Gynecol Cancer, 2005, 15 (3) : 195.
7Berek JS, Rertelsen K, duBois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements [J]. Ann Oncol, 1999, 10 (1): 87.
8Berek JS, Trope C, Vergote I. Surgery- during chemotherapy and at relapse of ovarian cancer [J]. Ann Oncol, 1999, 10 (11) : 3.
9Benedet JL, Hacker NF, Ngan Hys. FIGO staging classification and clinical practice guideline in the management of gynecologic cancer [M].New York: Elsevier, 2004:63 -65.
10Pfistercr J, Vergote I, Du Bois A, et al. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer[J]. Int J Gynecol Cancer, 2005, 15 (1): 36.
2Kuroki M, Arakawa F, Khare PD, et al. Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv)with a high affinity for CEA[J]. Anticancer Res, 2002, 20(6A): 4067～4071.
3Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors[J]. Clin J Oncol Nurs, 2004 ,8(2):163～8.
4Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation[J].Mol Cancer Ther, 2004, 3(4):465～72.
5Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer[J].Clin Colorectal Cancer, 2004, 3(4):205.
6Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.Nature, 2003, 421(6924): 756～60.
7Park BW, Kim KS, Heo MK, et al. Anti-HER2/neu peptide producing vector system for biologic therapy - is it possible to mass-produce the peptide? Yonsei Med J,2003,44(1):58～64.
8Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma[J].Ann Oncol, 2003,14 Suppl 1:i17～20.
9Makower D, Sparano JA, Wadler S, et al. A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma[J].Cancer Invest,2003, 21(2):177～84.
10Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy[J]. Clin Cancer Res, 2004, 10(2):784～93.
